26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Annexin-A1 enhances breast cancer growth and migration by promoting alternative macrophage polarization in the tumour microenvironment

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Macrophages are potent immune cells with well-established roles in the response to stress, injury, infection and inflammation. The classically activated macrophages (M1) are induced by lipopolysaccharide (LPS) and express a wide range of pro-inflammatory genes. M2 macrophages are induced by T helper type 2 cytokines such as interleukin-4 (IL4) and express high levels of anti-inflammatory and tissue repair genes. The strong association between macrophages and tumour cells as well as the high incidences of leukocyte infiltration in solid tumours have contributed to the discovery that tumour-associated macrophages (TAMs) are key to tumour progression. Here, we investigated the role of Annexin A1 (ANXA1), a well characterized immunomodulatory protein on macrophage polarization and the interaction between macrophages and breast cancer cells. Our results demonstrate that ANXA1 regulates macrophage polarization and activation. ANXA1 can act dually as an endogenous signalling molecule or as a secreted mediator which acts via its receptor, FPR2, to promote macrophage polarization. Furthermore, ANXA1 deficient mice exhibit reduced tumour growth and enhanced survival in vivo, possibly due to increased M1 macrophages within the tumor microenvironment. These results provide new insights into the molecular mechanisms of macrophage polarization with therapeutic potential to suppress breast cancer growth and metastasis.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Annexin A1 and glucocorticoids as effectors of the resolution of inflammation.

          Glucocorticoids are widely used for the management of inflammatory diseases. Their clinical application stems from our understanding of the inhibitory effect of the corticosteroid hormone cortisol on several components of the immune system. Endogenous and exogenous glucocorticoids mediate their multiple anti-inflammatory effects through many effector molecules. In this Opinion article, we focus on the role of one such effector molecule, annexin A1, and summarize the recent studies that provide insight into its molecular and pharmacological functions in immune responses. In addition, we propose a model in which glucocorticoids regulate the expression and function of annexin A1 in opposing ways in innate and adaptive immune cells to mediate the resolution of inflammation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cancer related inflammation: the macrophage connection.

            Tumor-associated macrophages (TAM) are key regulators of the link between inflammation and cancer. In the tumor microenvironment neoplastic cells shape the differentiation and functional orientation of TAM which, in turn, express several protumoral functions, including secretion of growth factors and matrix-proteases, promotion of angiogenesis and suppression of adaptive immunity. This review analyzes our current knowledge of TAM and their involvement in tumor development and progression. The interplay between TAM and neoplastic cells represents a promising target of future therapeutic approaches.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Formyl-peptide receptors revisited.

              Leukocytes accumulate at sites of inflammation and microbial infection in direct response to locally produced chemotactic factors, which signal through specific G protein-coupled receptors. The first chemotactic factors to be structurally defined were the N-formyl peptides. Unlike other leukocyte chemoattractants, N-formyl peptides could originate from either an endogenous source, such as the mitochondrial proteins of ruptured host cells, or an exogenous source, such as the proteins of invading pathogens. This suggests that the formyl-peptide receptor (FPR) and its variant FPRL1 (FPR-like 1) are involved in host defense against bacterial infection and in the clearance of damaged cells. Recently, additional, more complex, roles for these receptors have been proposed because FPR, and to a greater extent FPRL1, have been found to interact with a menagerie of structurally diverse pro- and anti-inflammatory ligands associated with different diseases, including amyloidosis, Alzheimer's disease, prion disease and HIV. How these receptors recognize such diverse ligands, which are the most important in vivo, and how they contribute to disease pathogenesis and host defense are basic questions currently under investigation that could lead to new therapeutic targets.
                Bookmark

                Author and article information

                Contributors
                lina_lim@nuhs.edu.sg
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                20 December 2017
                20 December 2017
                2017
                : 7
                : 17925
                Affiliations
                [1 ]ISNI 0000 0001 2180 6431, GRID grid.4280.e, Department of Physiology, , Yong Loo Lin School of Medicine, National University of Singapore (NUS), ; Singapore, Singapore
                [2 ]ISNI 0000 0001 2180 6431, GRID grid.4280.e, NUS Immunology Program, , Life Sciences Institute, NUS, ; Singapore, Singapore
                [3 ]ISNI 0000 0001 2180 6431, GRID grid.4280.e, Cancer Science Institute of Singapore, , NUS, ; Singapore, Singapore
                [4 ]ISNI 0000 0001 2180 6431, GRID grid.4280.e, Department of Pharmacology, Yong Loo Lin School of Medicine, , NUS, ; Singapore, Singapore
                [5 ]ISNI 0000 0001 2180 6431, GRID grid.4280.e, NUS Graduate School for Integrative Sciences and Engineering, , NUS, ; Singapore, Singapore
                [6 ]ISNI 0000 0004 0637 0221, GRID grid.185448.4, Singapore Immunology Network (SIgN), Agency for Science, , Technology and Research, ; Singapore, Singapore
                [7 ]ISNI 0000 0001 2180 6431, GRID grid.4280.e, Medical Science Cluster, Yong Loo Lin School of Medicine, , National University of Singapore, ; Singapore, Singapore
                [8 ]ISNI 0000 0004 0375 4078, GRID grid.1032.0, Curtin Medical School, Faculty of Health Sciences, , Curtin University, ; Perth, WA Australia
                Author information
                http://orcid.org/0000-0002-8950-6192
                Article
                17622
                10.1038/s41598-017-17622-5
                5738423
                29263330
                3d7571e8-20e6-497c-bebe-294075010dfd
                © The Author(s) 2017

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 8 March 2017
                : 29 November 2017
                Categories
                Article
                Custom metadata
                © The Author(s) 2017

                Uncategorized
                Uncategorized

                Comments

                Comment on this article